Ann: NWR Virtual Healthcare Conference Presentation, page-57

Par use an estimate of 10% of the OA market who are DISSATISFIED to obtain their figures. There is a reason they use this (conservative) figure.

AND so far, their data is derived from predominantly OA in grade 3 and 4 - AND the data looks good. The disease process at these grades has been active for many many years. 12 shots of Zilosul within 6 weeks. However it’s not going to be enough for some. Clearly.

But if we demonstrate DMOAD at grade 3 and 4 and then borrow an “early intervention principle” and administer the drug early in grade 2, once NSAIDS are truly ineffective) then my thoughts (along with others) would be that the drug modify the disease process earlier.

For those with truly chronic OA at end stage, perhaps in time, they need a sustained dosage of the molecule or other therapies in conjunction (plasma, stem cell, other) or Total Knee Replacement.